Omacetaxine Subcutaneous and Trifluoperazine Hydrochloride

• Generic Name: omacetaxine
• Dosage Forms: n.a.
• Other Brand Names: Synribo

Omacetaxine injection is used to treat chronic or accelerated phase chronic myeloid leukemia (CML). It is used in patients who have already received medicines for CML that did not work well. Leukemia is a type of cancer where the body makes abnormal white blood cells.

Omacetaxine is an antineoplastic (cancer) medicine. It interferes with the growth of cancer cells, which are eventually destroyed by the body. Since the growth of normal cells may also be affected by omacetaxine, other side effects can occur. Before you begin treatment, talk to your doctor about the benefits of omacetaxine as well as the possible risks of using it.

Omacetaxine is to be given only by or under the direct supervision of a doctor.

• Generic Name: trifluoperazine
• Dosage Forms: n.a.
• Other Brand Names: Stelazine

Treatment of schizophrenia.

American Psychiatric Association (APA) considers most atypical antipsychotic agents first-line drugs for management of the acute phase of schizophrenia (including first psychotic episodes). APA considers conventional antipsychotic agents first-line in patients with acute psychotic episodes who have been treated successfully in the past with, or who prefer, conventional agents.

Patients who do not respond to or tolerate one drug may be successfully treated with an agent from a different class or with a different adverse effect profile.

Short-term management of nonpsychotic anxiety in patients with generalized anxiety disorder.

Not established whether trifluoperazine is useful for the management of other nonpsychotic conditions in which anxiety or manifestations that mimic anxiety are evident (e.g., physical illness, organic mental conditions, agitated depression, character pathologies).

Because of the risks of toxicity, use only as an alternative to other less toxic anxiolytic agents (e.g., benzodiazepines) in most patients.

Efficacy not established for the management of behavioral complications in patients with mental retardation.